The 104-123 amino acid sequence of the β-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion

Cancer Research

Volumn 61, Issue 5, 2001, Pages 1768-1775

  Datta, K ^a   Sundberg, C ^a   Karumanchi, S A ^a   Mukhopadhyay, D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN KINASE C; SOMATOMEDIN C RECEPTOR;

AMINO ACID SEQUENCE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, RENAL CELL; CELL DIVISION; GENE PRODUCTS, TAT; HUMANS; KIDNEY NEOPLASMS; LIGASES; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035266403     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Renal cell carcinoma: Basic biology and clinical behavior
2. Renal cell carcinoma: Management of advanced disease
3. Systemic therapy for renal cell carcinoma
4. Chemotherapy for renal cell carcinoma
5. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells
6. Von Hippel-Lindau disease and sporadic renal cell carcinoma
7. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis
8. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma
9. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene
10. Detection of germline mutations in the von Hippel-Lindau disease gene by the primer specified restriction map modification method
11. Mutation of the von Hippel-Lindau disease gene in human renal cell carcinoma
12. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
13. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase
14. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2
15. Recombinant adenovirus expressing von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kipl
16. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity
17. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex
18. Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function
19. Studying interactions of four proteins in the yeast two-hybrid system: Structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/ cullin/F-box protein
20. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
21. Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function
22. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines
23. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant
24. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2
25. Inhibition of insulin-like growth factor-1-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer
26. The IGF-1 receptor in cell growth, transformation, and apoptosis
27. Autonomous functional domains of chemically synthesized human immunodeficiency vires tat trans-activator protein
28. Tat-mediated delivery of heterologous proteins into cells
29. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration
30. In vivo protein transduction: Delivery of a biologically active protein into the mouse
31. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
32. Invasion of veins in renal cell carcinoma-frequency, correlation, and prognosis
33. Signaling through scaffold, anchoring, and adaptor proteins
34. Somatic overgrowth associated with overexpression of insulin-like growth factor II
35. Effects of growth hormone and insulin-like growth factor I on renal growth and function
36. Protein kinase C-δ is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation
37. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
38. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
39. Up-regulation of vascular endothelial growth factor and its receptors in von Hippe/-Lindau disease-associated and sporadic hemangioblastomas
40. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity
41. The von Hippel-Lindau tumor suppressor protein: New perspectives